Commentary on "accounting for the interim safety monitoring of an adverse event upon termination of a clinical trial"

JEN-PEI LIU2018-09-102018-09-1020081054-3406http://www.scopus.com/inward/record.url?eid=2-s2.0-46749099813&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/338920cerivastatin; rofecoxib; clinical trial; drug efficacy; drug industry; drug safety; human; monitoring; note; priority journal; risk assessment; risk management; unspecified side effectCommentary on "accounting for the interim safety monitoring of an adverse event upon termination of a clinical trial"journal article10.1080/105434008020713372-s2.0-46749099813